This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Montalban, X. Search for Related Content PubMed PubMed Citation Articles by Montalban, X. Social Bookmarking                         What's this?

Overview of European pilot study of interferon β-1b in primary progressive multiple sclerosis

University Hospital Vall d'Hebron, Unitat de Neuroimmunologia Clinica, E-08035, Barcelona, Spain

This short monograph describes a trial of interferon β- 1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon β-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon β-1b in the MSFC score, T2 lesion volume and T1 lesion volume at 24 months were observed. Further study of interferon β-1b therapy in PPMS patients is warranted. Multiple Sclerosis (2004) 10, S62-S64

Key Words: Key words: primary progressive MS • interferon β- 1b • MRI • EDSS • MSFC

Multiple Sclerosis, Vol. 10, No. 1 suppl, S62-S64 (2004)
DOI: 10.1177/135245850401000111


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?